The Generalized Anxiety Disorder Market Size in the 7MM reached ~USD 1,560 million in 2023 and It is projected to grow at a significant CAGR by 2036, estimates DelveInsight

DelveInsight's " Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Generalized Anxiety Disorder Market Share @ Generalized Anxiety Disorder Market Outlook- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Generalized Anxiety Disorder Market Research Report
• In January 2026, MindMed rebranded to Definium Therapeutics, outlining multiple anticipated Phase III milestones in GAD in 2026. The company expects topline data from two pivotal Phase III studies of DT120 ODT in GAD, with results from Voyage anticipated in the second quarter of 2026 and Panorama in the second half of 2026.
• The overall count of individuals diagnosed with GAD in the United States was approximately 8,770 thousand in 2023, and these numbers are expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of GAD, with 1,460 thousand cases, followed by Italy and Spain in 2023. On the other hand, the UK had the lowest prevalent population in the European region in 2023.
• In 2023, Japan reported approximately 1,360 thousand diagnosed prevalent cases of GAD.
• Gender-specific diagnosed prevalent cases of GAD showed that females were more affected by GAD than males in the 7MM.
• As per DelveInsight's analysis, the diagnosed prevalent cases of GAD based on age were categorized into four groups: 18-29 years, 30-44 years, 45-59 years, and 60 years and above. The highest proportion of GAD cases was estimated in the 45-59 years age group in the 7MM, while the least cases were in the age group 18-29 years.
• The cases of GAD were classified based on severity levels, into mild, moderate, and severe categories. DelveInsight's estimations reveal that the highest number of severity-specific cases in the US was attributed to moderate cases, totaling 3,910 thousand, in 2023.
• The leading Generalized Anxiety Disorder Companies such as VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics Inc., Bionomics Limited, Receptor Life Sciences, MannKind Corporation, and others
• Promising Generalized Anxiety Disorder Pipeline Therapies such as MM-120, PH94B, Vilazodone (Viibryd), Intuniv (Guanfacine), BNC210, and others.

Discover which therapies are expected to grab the Generalized Anxiety Disorder market share @ Generalized Anxiety Disorder Market Outlook- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Generalized Anxiety Disorder Epidemiology Segmentation in the 7MM
• Generalized Anxiety Disorder Diagnosed Prevalent Cases
• Generalized Anxiety Disorder Age-specific Diagnosed Prevalent Cases
• Generalized Anxiety Disorder Gender-specific Diagnosed Prevalent Cases
• Generalized Anxiety Disorder Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Generalized Anxiety Disorder epidemiology trends @ Generalized Anxiety Disorder Prevalence- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Generalized Anxiety Disorder Emerging Drugs
• DT120 ODT (LSD D-Tartrate): Definium Therapeutics
DT120 orally disintegrating tablet is Definium Therapeutic's optimized form of lysergide D-tartrate (LSD), designed to enhance bioavailability, enable rapid absorption, and minimize gastrointestinal side effects using Catalent's Zydis fast-dissolve technology. DT120 ODT acts as a partial agonist at serotonin receptors, increasing brain connectivity, which may help alleviate symptoms of GAD by addressing underlying neural dysregulation.

• Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka
Ulotaront is an investigational trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor agonist being developed as a novel oral treatment for GAD. By targeting these receptors, ulotaront aims to modulate neurotransmitter activity differently from traditional anxiolytics, potentially offering a new mechanism of action for managing GAD. The drug is currently undergoing Phase II/III clinical trials in both the US and Japan to evaluate its efficacy and safety in treating GAD.

Generalized Anxiety Disorder Drugs Market Insights
Generalized Anxiety Disorder market lacks universally effective, fast-acting treatments with minimal side effects. This underscores the necessity for personalized, safer, and more accessible therapies to enhance outcomes for individuals with GAD. Nevertheless, the emerging pipeline for GAD treatments is not highly competitive, with few companies showing interest in developing therapies for this condition.

Generalized Anxiety Disorder Market Outlook
Generalized Anxiety Disorder has a diverse treatment classification associated with the disease landscape. The standard array of pharmacological agents employed in the management of GAD encompasses a diverse range, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), antiepileptics like pregabalin, tricyclic antidepressants (TCAs) that impact mood regulation, benzodiazepines offering rapid relief, antihistamines, atypical antipsychotics, and antioxidants.

To learn more about Generalized Anxiety Disorder treatment guidelines, visit @ Generalized Anxiety Disorder Treatment Market Landscape- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Generalized Anxiety Disorder Companies
VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics Inc., Bionomics Limited, Receptor Life Sciences, MannKind Corporation, and others

Generalized Anxiety Disorder Treatment Landscape
The primary treatment goal in GAD is to alleviate excessive, persistent worry and anxiety and to improve overall functioning and well-being. The standard array of pharmacological agents employed in the management of GAD encompasses a diverse range, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), antiepileptics like pregabalin, tricyclic antidepressants(TCAs) that impact mood regulation, benzodiazepines offering rapid relief, antihistamines, atypical antipsychotics, and antioxidants

Learn more about the FDA-approved drugs for Generalized Anxiety Disorder @ Drugs for Generalized Anxiety Disorder Treatment- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Generalized Anxiety Disorder Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Generalized Anxiety Disorder Companies- VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics Inc., Bionomics Limited, Receptor Life Sciences, MannKind Corporation, and others
• Generalized Anxiety Disorder Pipeline Therapies- MM-120, PH94B, Vilazodone (Viibryd), Intuniv (Guanfacine), BNC210, and others.
• Generalized Anxiety Disorder Market Dynamics: Generalized Anxiety Disorder Market Drivers and Barriers

Discover more about Generalized Anxiety Disorder Drugs in development @ Generalized Anxiety Disorder Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Generalized Anxiety Disorder Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary of Generalized Anxiety Disorder
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey of GAD
10. Emerging Therapies
11. GAD: Market Analysis
12. Key Opinion Leaders' Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.